Through digital-first process design, CMAC researchers decrease the material required for API development by an order of magnitude.
Read More
Researchers at Eli Lilly & Company have successfully applied CMAC’s impurity rejection workflow in clinical development, achieving up to 100% rejection of problematic impurities.
Read More